Themis Medicare gets add on approval for drug VIRALEX; Stock plunges over 5%

19 May 2022 , 10:44 AM

Themis Medicare Ltd. (Themis), a Pharmaceutical company headquartered in Mumbai has announced the add on approval for drug VIRALEX by the Drug Controller General of India (DCGI) for treatment of Influenza and other Acute Viral Respiratory Infections (AVRI), Mucocutaneous herpes, Genital wart and Subacute Sclerosing Panencephalitis (SSPE).

VIRALEX (Inosine Pranobex) is an immunomodulatory agent with broad spectrum antiviral properties. Earlier VIRALEX was approved by DCGI for restricted emergency use in Covid 19 patients based on the results of two Randomized controlled trials (RCT) in 499 Indian patients.

Inosine Pranobex is in clinical use for >50 years since its first approval internationally. It is currently marketed in >70 countries across the world including many advance countries for the treatment of several viral diseases with established efficacy and safety profile.

VIRALEX strengthens the immune system through modulation of T-cell proliferation, T-cell function, natural killer cell activity, phagocytosis, and also by modulating certain cytokines, and enhances body’s immune response to various viral infections.

NK cells are the first line defense against viral infections. VIRALEX enhances human NK cell cytotoxicity in two ways by increasing NK cell numbers and facilitating identification of virus-infected cell by NK cells by NKG2D ligand expression.

Based on world wide experience, the drug offer clinical benefits to the patients and address the unmet medical need in management of various viral infections, especially influenza and AVRI.

According to Themis, VIRALEX is manufactured at an EU-GMP-certified facility with the highest safety standards and stringent manufacturing protocols in place, and the medication is available on prescription in the form of a 500 mg tablet at an affordable price.

At around 10:46 AM, Themis Medicare was trading at Rs826.95 apiece down by Rs48.05 or 5.49% from its previous closing of Rs875 apiece on the BSE.